In accordance with their inhibitory effect on brain inflammation, beneficial effects of PPAR-γ agonists or AT1 inhibition have also been observed in a number of processes mediated by microglial activation and neuroinflammation, including animal models of Alzheimer's disease [67-69], brain ischemia [40,70,71], multiple sclerosis [63,64,72], traumatic brain injury [73] and aging [15,59,74]. This evidence concerns the gene PPARG and Alzheimer disease.